Early Dawn of Curative Effect and Bumpy Road Ahead for First-Line Treatment: Evaluation on Application of Immune Checkpoint Inhibitor in Advanced Non-Small Cell Lung Cancer With <i>HER2</i> Alterations

LIU Xin-yu; REN Sheng-xiang; SUN Yue-li

doi:10.12019/j.issn.1671-5144.2022.04.002

LIU Xin-yu, REN Sheng-xiang, SUN Yue-li. Early Dawn of Curative Effect and Bumpy Road Ahead for First-Line Treatment: Evaluation on Application of Immune Checkpoint Inhibitor in Advanced Non-Small Cell Lung Cancer With HER2 Alterations[J]. Journal of Evidence-Based Medicine, 2022, 22(4): 198-201. DOI: 10.12019/j.issn.1671-5144.2022.04.002

Citation:

LIU Xin-yu, REN Sheng-xiang, SUN Yue-li. Early Dawn of Curative Effect and Bumpy Road Ahead for First-Line Treatment: Evaluation on Application of Immune Checkpoint Inhibitor in Advanced Non-Small Cell Lung Cancer With HER2 Alterations[J]. Journal of Evidence-Based Medicine, 2022, 22(4): 198-201. DOI: 10.12019/j.issn.1671-5144.2022.04.002

Citation:

LIU Xin-yu, REN Sheng-xiang, SUN Yue-li. Early Dawn of Curative Effect and Bumpy Road Ahead for First-Line Treatment: Evaluation on Application of Immune Checkpoint Inhibitor in Advanced Non-Small Cell Lung Cancer With HER2 Alterations[J]. Journal of Evidence-Based Medicine, 2022, 22(4): 198-201. DOI: 10.12019/j.issn.1671-5144.2022.04.002

Early Dawn of Curative Effect and Bumpy Road Ahead for First-Line Treatment: Evaluation on Application of Immune Checkpoint Inhibitor in Advanced Non-Small Cell Lung Cancer With HER2 Alterations

Graphical Abstract

Graphical Abstract

Abstract

FullText(HTML)

References (12)

Early Dawn of Curative Effect and Bumpy Road Ahead for First-Line Treatment: Evaluation on Application of Immune Checkpoint Inhibitor in Advanced Non-Small Cell Lung Cancer With HER2 Alterations

Graphical Abstract

Catalog

Export File

Citation

Format

Content